DORVAL, QC, July 8, 2014 /CNW Telbec/ - Warnex Inc. (TSXV: WNX.H) ("Warnex") is pleased to announce the completion of its previously announced amalgamation (the "Amalgamation") with a wholly-owned subsidiary of Diagnos Inc. ("Diagnos") (TSXV: ADK).
Shareholders of Warnex will receive one common share of Diagnos (a "Diagnos Share") for each common share of Warnex (a "Warnex Share") held. Each shareholder of Warnex and of Diagnos will also be entitled receive one half warrant (a "Warrant") to purchase one Diagnos Share for each Warnex Share or Diagnos Share held. Once issued, each whole Warrant will be exercisable at a price of $0.10 per share for a period of twelve months.
The Warnex Shares will be delisted from trading on the NEX and the amalgamated entity will apply to cease being a reporting issuer under the securities legislation of each province of Canada where it is a reporting issuer.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For further information identifying known risks and uncertainties, relating to financial resources, liquidity risk, volatility of share price and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Warnex Inc.
For further information: Michael Singer, Chairman of the Board of Directors, Warnex Inc., Tel: (514) 940-3600, email@example.com